Search

Your search keyword '"Camm, A. John"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Camm, A. John" Remove constraint Author: "Camm, A. John" Publisher elsevier bv Remove constraint Publisher: elsevier bv
135 results on '"Camm, A. John"'

Search Results

2. Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm

3. Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings

5. Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry

6. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation

7. Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry

8. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial

9. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

10. PO-01-133 REAL-WORLD COMPARISON OF DRONEDARONE VS. SOTALOL IN ANTI-ARRHYTHMIC DRUG NAÏVE PATIENTS WITH ATRIAL FIBRILLATION

11. MP-453091-1 EFFECT OF ETRIPAMIL NASAL SPRAY ON VENTRICULAR RATE IN PATIENTS EXPERIENCING SYMPTOMATIC ATRIAL FIBRILLATION

15. Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study

20. PO-668-01 ORALLY INHALED FLECAINIDE FOR THE CONVERSION OF RECENT-ONSET, SYMPTOMATIC ATRIAL FIBRILLATION TO SINUS RHYTHM: RESULTS FROM THE INSTANT PHASE 2 STUDY

21. Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening

23. Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial

24. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants

27. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

28. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry

29. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

32. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

33. The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban

34. Reply

35. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)

36. Global Prospective Safety Analysis of Rivaroxaban

38. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden

39. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries

40. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial

41. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial

44. TIME-TRENDS IN ANTITHROMBOTIC MANAGEMENT OF PATIENTS WITH AF/FLUTTER TREATED WITH CORONARY STENTS: AN INTERNATIONAL MULTICENTER RESTROSPECTIVE ANALYSIS

45. TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY

47. THE PRESCRIBING OF ANTIPLATELET THERAPY ONLY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY

48. EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY

49. Reference values of heart rate variability

50. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

Catalog

Books, media, physical & digital resources